To identify lipid metabolism-associated hub genes with diagnostic and prognostic relevance in acute myeloid leukemia (AML) through comprehensive transcriptomic analysis.
Key Findings:
Lipid metabolism-related pathways were significantly altered in AML samples, indicating a potential target for therapeutic intervention.
MTMR2 was identified as a candidate biomarker, showing marked upregulation in AML across independent datasets, suggesting its role in disease progression.
High MTMR2 expression correlated with poorer overall survival and altered immune-cell infiltration patterns, highlighting its prognostic value.
Exploratory clinical analysis indicated lower ApoA1 and LDL-C levels and higher TG levels in AML patients compared to healthy controls, suggesting metabolic dysregulation.
Interpretation:
MTMR2 is associated with lipid metabolism in AML and shows potential as a biomarker for diagnosis and prognosis, warranting further investigation into its mechanistic role.
Limitations:
The study relied on specific GEO datasets and may not encompass all AML subtypes, which could limit the generalizability of the findings.
Further validation in larger independent cohorts is needed to confirm the clinical relevance of MTMR2 as a biomarker.
Conclusion:
MTMR2 is a lipid metabolism-associated candidate biomarker in AML, warranting further mechanistic and clinical validation to explore its potential in therapeutic targeting.
